本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Metagenomi Technologies, LLC

1.39
+0.02001.46%
盤後1.390.00000.00%17:26 EDT
成交量:22.16萬
成交額:31.24萬
市值:5,219.00萬
市盈率:-0.59
高:1.45
開:1.40
低:1.38
收:1.37
52周最高:3.95
52周最低:1.23
股本:3,754.68萬
流通股本:2,527.67萬
量比:1.07
換手率:0.88%
股息:- -
股息率:- -
每股收益(TTM):-2.3600
每股收益(LYR):-2.3634
淨資產收益率:-44.67%
總資產收益率:-21.99%
市淨率:0.33
市盈率(LYR):-0.59

資料載入中...

公司資料

公司名字:
Metagenomi Technologies, LLC
交易所:
NASDAQ
成立時間:
2016
員工人數:
119
公司地址:
5959 Horton Street,7th Floor,Emeryville,California,United States
郵編:
94608
電話:
傳真:
- -
簡介:
Metagenomi Therapeutics, Inc.最初於2016年9月成立,並於2018年作為特拉華州有限責任公司開始其現有業務。該公司是一家體內基因編輯公司,專註於利用從宏基因組學中獲得的專有基因編輯工具開發治癒性基因藥物。其全資主導項目MGX-001旨在治療血友病A,並通過多種編輯方式持續推進針對遺傳性疾病的研發管線。

董事

名稱
職位
Brian C. Thomas
Co-Founder, Chief Executive Officer, Chair of the Board and Director
Jian Irish
President, Chief Operating Officer and Director
Willard Dere
Lead Independent Director
Eric Bjerkholt
Director
Juergen Eckhardt
Director

股東

名稱
職位
Brian C. Thomas
Co-Founder, Chief Executive Officer, Chair of the Board and Director
Jian Irish
President, Chief Operating Officer and Director
Matthew L. Wein
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
Pamela Wapnick
Chief Financial Officer
Sarah Noonberg
Chief Medical Officer